Gilead Sciences has revised its 2026 sales forecast for Yeztugo (lenacapivir), its twice-yearly HIV pre-exposure prophylaxis (PrEP) medication. Following a... Read more
Category: Uncategorized
Ministry of Health proposes establishing 2 new Departments through organizational restructuring
The Ministry of Health (MoH) has submitted a draft Decree on its functions, duties, and organizational structure to the Ministry... Read more
Electrical Shock: Hard To See, Happens In Seconds
Electrical shock is the kind of accident that gives you no warning. It happens fast—and even a brief contact can... Read more
AI as a Catalyst: Freeing Organizations from the Weight of Legacy
Insights for Executive Leadership A company’s greatest constraint is often its own corporate memory. Legacy workflows and entrenched assumptions act... Read more
Strategic Pitfalls: When Long-term Partnerships Undermine Profitability
Professional Insights for Healthcare Leaders Sales organizations frequently compromise their own leverage when dealing with established clients. Rather than capitalising... Read more
Kenvue beats first-quarter estimates amid pending $40 billion acquisition by Kimberly-Clark
Kenvue Inc., the maker of Tylenol, beat Wall Street estimates for first-quarter revenue and profit on Thursday. The positive performance... Read more
GSK licenses Halozyme ENHANZE for subcutaneous cancer drugs, including ADCs
Halozyme Therapeutics Inc. and GSK have entered into a global collaboration and license agreement. Under the terms, GSK has licensed... Read more
Altasciences and Certara partner to accelerate early-phase drug development
Altasciences, an integrated drug development solution company, and Certara, a global leader in model-informed drug development, have launched a strategic... Read more
Blackstone Life Sciences invests $250M in Anagram Therapeutics for Pancreatic Enzyme Replacement Therapy
Blackstone Life Sciences is making a $250 million investment in Anagram Therapeutics, a clinical-stage biopharmaceutical company. The funding is designated... Read more









